192 related articles for article (PubMed ID: 21562302)
21. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M
Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
[TBL] [Abstract][Full Text] [Related]
22. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
23. The role of glimepiride in the effective management of Type 2 diabetes.
Davis SN
J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
[TBL] [Abstract][Full Text] [Related]
24. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
Charbonnel B
Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
[No Abstract] [Full Text] [Related]
25. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
26. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Massi-Benedetti M; Orsini-Federici M
Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
[TBL] [Abstract][Full Text] [Related]
27. The therapeutic efficacy of rosiglitazone is enhanced in sulphonylurea-treated patients with type 2 diabetes.
Itakura H; Abbasi F; Lamendola C; Basina M; Reaven G
Diabetes Obes Metab; 2008 Aug; 10(8):685-7. PubMed ID: 18476981
[No Abstract] [Full Text] [Related]
28. Overview of current therapeutic options in type 2 diabetes. Rationale for combining oral agents with insulin therapy.
Buse JB
Diabetes Care; 1999 Apr; 22 Suppl 3():C65-70. PubMed ID: 10189565
[No Abstract] [Full Text] [Related]
29. Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria.
Winkelmayer WC; Stedman MR; Pogantsch M; Wieninger P; Bucsics A; Asslaber M; Bauer R; Burkhardt T; Schautzer A; Brookhart MA;
Pharmacoepidemiol Drug Saf; 2011 Jan; 20(1):57-65. PubMed ID: 21182153
[TBL] [Abstract][Full Text] [Related]
30. Type 2 diabetes: glycemic targets and oral therapies for older patients.
Lardinois CK
Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
[TBL] [Abstract][Full Text] [Related]
31. Can thiazolidinediones delay disease progression in type 2 diabetes?
Leiter LA
Curr Med Res Opin; 2006 Jun; 22(6):1193-201. PubMed ID: 16846552
[TBL] [Abstract][Full Text] [Related]
32. [Therapeutic approaches to improve blood glucose control in a patient with type 2 diabetes on a metformin-sulfonylurea combination].
Scheen AJ; Paquot N
Rev Med Liege; 2011 Apr; 66(4):215-21. PubMed ID: 21638841
[TBL] [Abstract][Full Text] [Related]
33. Glycemic durability of monotherapy for diabetes.
Garg R
N Engl J Med; 2007 Mar; 356(13):1379; author reply 1380. PubMed ID: 17402165
[No Abstract] [Full Text] [Related]
34. [Rosiglitazone: clinical data].
Blickle JF
Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 2):1S27-33. PubMed ID: 12037505
[No Abstract] [Full Text] [Related]
35. Thiazolidinediones and clinical outcomes in type 2 diabetes.
Retnakaran R; Zinman B
Lancet; 2009 Jun; 373(9681):2088-90. PubMed ID: 19501899
[No Abstract] [Full Text] [Related]
36. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
Johnson JA; Majumdar SR
Am Heart J; 2004 Dec; 148(6):e27; author reply e28. PubMed ID: 15632864
[No Abstract] [Full Text] [Related]
37. [Not Available].
Viardot A
Ther Umsch; 2017; 74(8):423-431. PubMed ID: 29461148
[No Abstract] [Full Text] [Related]
38. Pharmacological treatment of type 2 diabetes.
Hermans MP; Buysschaert M
Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
[No Abstract] [Full Text] [Related]
39. Insulin: thoroughly modern therapy.
Isley WL
Endocr Pract; 2004; 10(3):289-90. PubMed ID: 15310550
[No Abstract] [Full Text] [Related]
40. Glycemic durability of monotherapy for diabetes.
Rathmann W; Kostev K; Haastert B
N Engl J Med; 2007 Mar; 356(13):1378-9; author reply 1380. PubMed ID: 17392313
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
